Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context

Pascal Mertens, Nathalie De Vos, Delphine Martiny, Christian Jassoy, Ali Mirazimi, Lize Cuypers, Sigi Van den Wijngaert, Vanessa Monteil, Pierrette Melin, Karolien Stoffels, Nicolas Yin, Davide Mileto, Sabrina Delaunoy, Henri Magein, Katrien Lagrou, Justine Bouzet, Gabriela Serrano, Magali Wautier, Thierry Leclipteux, Marc Van Ranst, Olivier Vandenberg, LHUB-ULB SARS-CoV-2 Working Diagnostic Group, Béatrice Gulbis, Françoise Brancart, François Bry, Brigitte Cantinieaux, Francis Corazza, Fréderic Cotton, Maud Dresselhuis, Bhavna Mahadeb, Olivier Roels, Jacques Vanderlinden, Pascal Mertens, Nathalie De Vos, Delphine Martiny, Christian Jassoy, Ali Mirazimi, Lize Cuypers, Sigi Van den Wijngaert, Vanessa Monteil, Pierrette Melin, Karolien Stoffels, Nicolas Yin, Davide Mileto, Sabrina Delaunoy, Henri Magein, Katrien Lagrou, Justine Bouzet, Gabriela Serrano, Magali Wautier, Thierry Leclipteux, Marc Van Ranst, Olivier Vandenberg, LHUB-ULB SARS-CoV-2 Working Diagnostic Group, Béatrice Gulbis, Françoise Brancart, François Bry, Brigitte Cantinieaux, Francis Corazza, Fréderic Cotton, Maud Dresselhuis, Bhavna Mahadeb, Olivier Roels, Jacques Vanderlinden

Abstract

Introduction: COVID-19 Ag Respi-Strip, an immunochromatographic (ICT) assay for the rapid detection of SARS-CoV-2 antigen on nasopharyngeal specimen, has been developed to identify positive COVID-19 patients allowing prompt clinical and quarantine decisions. In this original research article, we describe the conception, the analytical and clinical performances as well as the risk management of implementing the COVID-19 Ag Respi-Strip in a diagnostic decision algorithm. Materials and Methods: Development of the COVID-19 Ag Respi-Strip resulted in a ready-to-use ICT assay based on a membrane technology with colloidal gold nanoparticles using monoclonal antibodies directed against the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen. Four hundred observations were recorded for the analytical performance study and thirty tests were analyzed for the cross-reactivity study. The clinical performance study was performed in a retrospective multi-centric evaluation on aliquots of 328 nasopharyngeal samples. COVID-19 Ag Respi-Strip results were compared with qRT-PCR as golden standard for COVID-19 diagnostics. Results: In the analytical performance study, the reproducibility showed a between-observer disagreement of 1.7%, a robustness of 98%, an overall satisfying user friendliness and no cross-reactivity with other virus-infected nasopharyngeal samples. In the clinical performance study performed in three different clinical laboratories during the ascendant phase of the epidemiological curve, we found an overall sensitivity and specificity of 57.6 and 99.5%, respectively with an accuracy of 82.6%. The cut-off of the ICT was found at CT <22. User-friendliness analysis and risk management assessment through Ishikawa diagram demonstrate that COVID-19 Ag Respi-Strip may be implemented in clinical laboratories according to biosafety recommendations. Conclusion: The COVID-19 Ag Respi-Strip represents a promising rapid SARS-CoV-2 antigen assay for the first-line diagnosis of COVID-19 in 15 min at the peak of the pandemic. Its role in the proposed diagnostic algorithm is complementary to the currently-used molecular techniques.

Keywords: COVID-19; SARS-CoV-2; antigen; diagnostic; immunochromatographic test.

Copyright © 2020 Mertens, De Vos, Martiny, Jassoy, Mirazimi, Cuypers, Van den Wijngaert, Monteil, Melin, Stoffels, Yin, Mileto, Delaunoy, Magein, Lagrou, Bouzet, Serrano, Wautier, Leclipteux, Van Ranst, Vandenberg and LHUB-ULB SARS-CoV-2 working diagnostic group.

Figures

Figure 1
Figure 1
Standard operating procedure SARS-CoV-2 Respi-Strip® from Coris BioConcept.
Figure 2
Figure 2
Proposal for a diagnostic decision algorithm.
Figure 3
Figure 3
Ishikawa diagram of rapid SARS-CoV-2 diagnostic tests for Clinical Labs' implementation. BSL-2, Biosafety Level 2; FAMHP, Belgian Federal Agency for Medicines and Health Products; FFP2, Filtering Facepiece Respirator Class 2; FPS Health, Belgian Federal Public Service Health, Food Chain Safety and Environment; IVDR, European Regulation 2017/746 on in vitro Diagnostic Medical Devices.

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A novel Coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. 10.1056/NEJMoa2001017
    1. Rubin EJ, Baden LR, Morrissey S. Audio interview: new research on possible treatments for Covid-19. N Engl J Med. (2020) 382:e30. 10.1056/NEJMe2005759
    1. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. (2020) 1:9 10.1007/s00330-020-06801-0
    1. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ. (2020) 27:1451–54. 10.1038/s41418-020-0530-3
    1. Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY, et al. . Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol. (2004) 42:2629–35. 10.1128/JCM.42.6.2629-2635.2004
    1. Kogaki H, Uchida Y, Fujii N, Kurano Y, Miyake K, Kido Y, et al. . Novel rapid immunochromatographic test based on an enzyme immunoassay for detecting nucleocapsid antigen in SARS-associated coronavirus. J Clin Lab Anal. (2005) 19:150–9. 10.1002/jcla.20070
    1. Di B, Hao W, Gao Y, Wang M, Wang YD, Qiu LW, et al. . Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients. Clin Diagn Lab Immunol. (2005) 12:135–40. 10.1128/CDLI.12.1.135-140.2005
    1. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yan S, et al. . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. EMI. (2020) 9:221–36. 10.1080/22221751.2020.1719902
    1. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro Diagnostic Medical Devices Available online at:
    1. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro Diagnostic Medical Devices and Repealing Directive 98/79/EC and Commission Decision 2010/227/EU (Text with EEA relevance) Available online at:
    1. Sandberg S, Nordin G, Mårtensson A, Grinsted P, Jensen E, Eide C, et al. . Laboratory equipment for primary health care should be tested by independent authorities. Scandinavian SKUP is a good alternative. Lakartidningen. (2008) 105:3334–6, 3338–9.
    1. Bussmann BM, Reiche S, Jacob LH, Braun JM, Jassoy J. Antigenic and cellular localisation analysis of the severe acute respiratory syndrome coronavirus nucleocapsid protein using monoclonal antibodies. Virus Res. (2006) 122:119–26. 10.1016/j.virusres.2006.07.005
    1. Corman V, Bleicker T, Brünink S, Drosten C, Landt O, Molbio T, et al. Diagnostic Detection of Wuhan Coronavirus 2019 by Real-Time RT-PCR. (2020). Available online at:
    1. Clancy A, Crowley B, Niesters H, Herra C. The development of a qualitative real-time RT-PCR assay for the detection of hepatitis C virus. Eur J Clin Microbiol Infect Dis. (2008) 27:1177–82. 10.1007/s10096-008-0556-9
    1. Busson L, Bartiaux M, Brahim S, Konopnicki D, Dauby N, Gérard M, et al. . Prospective evaluation of diagnostic tools for respiratory viruses in children and adults. J Virol Methods. (2019) 266:1–6. 10.1016/j.jviromet.2019.01.006
    1. Corman Victor M, Olfert L, Marco K, Richard M, Adam M, Chu Daniel KW, et al. . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. (2020) 25:2000045. 10.2807/1560-7917.ES.2020.25.3.2000045
    1. Ishikawa K. Guide to Quality Control. Asian Productivity Organization; ISBN 92–833-1036–5 (1976).
    1. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections — the state of the art. Emerg Microbes Infect. (2020) 9:747–56. 10.1080/22221751.2020.1745095
    1. Diao B, Wen K, Chen J, Liu Y, Yuan Z, Han C, et al. Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein. medRxiv. (2020) 10.1101/2020.03.07.20032524
    1. Blaschke AJ, McKevitt M, Ampofo K, Lewis T, Chai H, Guo Y, et al. . Midturbinate swabs are comparable to nasopharyngeal swabs for quantitative detection of respiratory syncytial virus in infants. J Pediatric Infect Dis Soc. (2019) 8:554–8. 10.1093/jpids/piy115
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Eng J Med. (2020) 10.1056/NEJMoa2001282
    1. Vandenberg O, Durand G, Hallin M, Diefenbach A, Gant V, Murray P, et al. . Consolidation of clinical microbiology laboratories and introduction of transformative technologies. Clin Microbiol Rev. (2020) 33:e00057-19. 10.1128/CMR.00057-19

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit